MVD patients still have a high incidence of adverse cardiovascular events after PCI, which is closely related to the progression of NCCLs. The correlation between the level of inflammation and risk factors of coronary heart disease in MVD patients after PCI and the progression of NCCLs lesions can be used as a basis for accurate assessment and early intervention of MVD patients after PCI. Our purpose is to reduce the incidence of adverse cardiovascular events, thereby reducing patient mortality and improving patient outcomes.

Kaiwen Liu, Guipeng Wang. Non-offender Vascular Disease in Patients with Coronary Ceart Disease after PCI. International Journal of Frontiers in Medicine (2023), Vol. 5, Issue 10: 23-27. https://doi.org/10.25236/IJFM.2023.051004.

[1] World Health Organization. Cardiovascular disease (CVD). https://www.who.int/healthtopics/cardiovascular-diseases, 2020-09-24.

[2] National Health Commission. China Health Statistics Yearbook 2019 edition [M]. Beijing: China Union Medical University Press,2019:284.

[3] Hu S S, Gao R L, Liu L S, et al. Summary of Chinese Cardiovascular disease Report 2018 [J]. Chin J Circulation,2019,34(3):209-220.

[4] Ben-GalY, MohrR, FeitF,etal. Surgical Versus Percutaneous Coronary Revascularizationfor Multivessel Diseasein Diabetic Patients With Non-ST-Segment-Elevation Acute Coronary Syndrome[J]. Circulation Cardiovascular Interventions, 2015, 8 (6) : 16-21.

[5] Xu A P. Clinical efficacy of complete revascularization in patients with multivessel coronary artery disease [J]. Chinese Medicine Guide,2015(30):58-59. (in Chinese)

[6] BundhunPK,WuZJ,ChenMH.Coronaryr teryby passsurgery compared with percutaneous coronary interventionsin patients with insulin-treated type2 diabetes mellitus:asystema ticre view and meta-analysis of 6randomized controlled trials[J].Cardiovascular Diabetology,2016,15(1):2.

[7] Ross R. he pathogenesis of atherosclerosis: aperspective for the 1990s[J]. Nature, 1993,362 (6423) : 801-809. 

[8] KereiakesDJ. Reassessing the importance of complete versus incomplete coronary revascu Larization [J] RevCardiovascMed, 2014, (1) : 24 to 30.

[9] Tsiantoulas D, Diehl CJ, Witztum JL,et al. B cells and humoral immunity in atherosclerosis[J]. Circ Res. 2014 May 23; 114 (11) : 1743-56.

[10] Braunwald E, Antman, EM, Beasley, JW, etc. ACC/AHA guidelines for the management of patients with unstabe angina andnon-ST-segment elevationmyocar dialinfarction.Areport of the American College of Cardiology/American Heart Association Task Forceon Practice Guidelines Committee on the M[J]. Journal of the American College of Cardiology.2000,36(3).970-1062.

[11] Ridker PM,Everett BM,Thuren T,etal.Antiinflammatory therapy withcanakinumab for atheroscl erotic Diseases [J] NEnglJMed, 2017377 (12) : 1119-1131.

[12] BautersC, IsnerJM Thebiology of restenosis [J]. Prog Cardiovasc Dis, 1997, 40 (2) : 107-116.

[13] Ibanez B, James S, Agewall S, et al. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST - segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST - segment eleva-tion of the European Society of Cardiology ( ESC) [J] . Eur Heart J,2018, 39(2 ) : 119 - 177 

[14] Smits PC, Abdel - Wahab M, Neumann FJ, et al. Fractional flow re-serve -guided multivessel angioplasty in myocardial infarction [J] .New Engl J, 2017 , 376(13) : 1234-1244

[15] Mehta SR, Wood DA, Storey RF, et al. Complete revascularization with multivessel PCI for myocardial infarction[J] . New Engl J, 2019 ,381 (15) : 1411 - 1421

[16] Pasceri V, Patti G, Pelliccia F, et al. Complete revascularization dur-ing primary percutaneous coronary intervention reduces death and myo-cardial infarction in patients with multivessel disease MetaAnalysis and Meta - Regression of Randomized Trials[J] . JACC Cardiovasc Interv,2018, 11(9) : 833 - 843

[17] Hu PT, Jones WS, Glorioso TJ, et al. Predictors and outcomes of staged versus one - time multivessel revascularization in multivessel coronary artery disease Insights From the VA CART Program [J] .JACC Cardiovasc Interv, 2018 , 11 (22) : 2265 - 2273

[18] GlaserR, SelzerF, FaxonDP, LaskeyWK, CohenHA, SlaterJ, DetreKM,WilenskyRL.Clicinal progression of incidental,asympto Maticles ionsdi scovered during culpritvessel coronary intervention [J]. Circulation, 2005111, (2) : 143-149.

[19] Yang YL, Wu CH, Hsu PF, et al. Systemic immune-inflammation index (SII) predicted clinical outcome in patients with coronary artery disease. Eur J Clin Invest. 2020; 50(5):e13230. 

[20] Candemir M, Kiziltunc E, Nurkoc S,et al. Relationship Between Systemic Immune-Inflammation Index (SII) and the Severity of Stable Coronary Artery Disease. Angiology. 2021; 72 (6) : 575-581.

[21] NakachiT,KosugeM,HihiK,EbinaT,HashibaK,MitsuhashiT,EndoM,UmemuraS,KimuraK.Creactive proteine levation and rapidang iographi cprogressiono fnoncul pritlesion inpatien tswithnon-ST-segmente levationa cutecoronary Syndrome [J] CirculationJournal, 2008 regulation (12) : 1953-1959.

[22] Lemesle G,deLabriolle A,Bonello L,Torguson R,Kaneshige K,Xue Z,Suddath WO,Satler LF,Kent KM, Lindsay J,Pichard AD,Waksman R.Incidence,predictors,andoutcomeofnew,subsequent lesions treated with percutaneou scoronary interventionin patients presenting with myocardialinf arction[J]. AmJ Cardial, 2009,103(9):1189-1195.

[23] Xu YL,LiJJ,XuB,Zhu CG,YangYJ,Chen JL,Qiao SB,Yuan JQ,Qin XW,Ma WH,Yao M,Liu HB,Wu YJ, Chen J,You SJ,Dai J,Xia R,Gao RL.Increased plasma C-reactive protein level predicts rapid progression of non-target atherosclerotic lesions in patientswith stable angina after stenting[J].Chin Med J (Engl). 2011; 124 (19) : 3022-9.

[24] Zheng J L, Lu L, Hu J, et al. Increased serum YKL-40andC-reactive protein levelsa reasso ciated with angiographicles ionprogressionin patients with Coronaryartery diseases. [J]. Journal of Atherosclerosis. 2010210 (2).

[25] Braunwald, E, Antman, EM, Beasley, JW, etc. ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the M[J].Journal of the American College of Cardiology.2000,36(3).970-1062.

[26] MURTHY P, ZENATI MS, AL ABBAS AI, Prognostic Value of the Systemic Immune system. Inflammation Index(SII)After Neoadjuvant Therapy for Patients with Resected Pancreatic Cancer[J]. Ann Surg Oncol, 2020,27 (3) : 898-906.

[27] de Waha S, Patel M R, Granger C B, et al. Relationship between microvascular obstruction and adverse events following primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: an individual patient data pooled analysis from seven randomized trials [J]. Eur Heart J, 2017, 38(47):

[28] LI J P, Zhu M F, Chen L. Research status of the relationship between inflammatory factors and acute coronary syndrome [J]. Hebei Med, 2015,21 (6) : 1008-1010.

[29] Li Y L, Wang J X, Sun Y L, et al. Effects of early rehabilitation on inflammatory factors and cardiopulmonary function in patients with acute coronary syndrome after percutaneous coronary intervention [J]. Journal of Integrated Traditional Chinese and Western Medicine Cardio-Cerebrovascular Disease,2017,015(008):979-982.

[30] Ndrepepa G, Neumarm FJ, Schulz S, Fusaro M, Cassese S, Byrne RA, Richardt G.Incidence and prognostic value of bleeding atter percutaneous coronary intervention in patients older than 18 years of age [J] . Catheter Cardiovasc Interv, 2014, 83(2): 182-189. 

[31] Niccoli G, Montone RA, Ferrance G, Crea F. The evolving role of inflamma-tory biomakers in risk assessment after stent implantation[J]. J Am Coli Cardiol, 2010, 56(22): 1783-1793.

[32] Gao Daishun. The relationship between platelet index and the progression of non-culprit vascular disease in patients with coronary heart disease after percutaneous coronary intervention [D]. The First Affiliated Hospital of Zhengzhou University. 2019. 

[33] Chen Wenming, Li Dongbao, Chen Hui, Li Hongwei, Zhao Jie, Zhao Huiqiang, Liang Siwen, Ding Xiaosong. Predictors of rapid progression of non-culprit coronary lesions after stent implantation [J]. Journal of Capital Medical University, 2013, 34: 90-94.

[34] Morice MC, Serruys PW, Sousa JE. Randomized study with the sirolimus-coated Bx Velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions.19 A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization [J]. N Engl J Med, 2002, 346(23): 1773-1780.

[35] Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, Shaughnessy CO, Caputo RP, Kereiakes DJ, Williams DO, Teirstein PS, Jaeger JL. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery [J]. N Engl J Med, 2003, 349(14):1315-1323. 

[36] Stone GW, Ellis SG, Cox DAl, Hermiller J, Shaughnessy CO, Mann JT. A polymer-based, paclitaxel-eluting stent in patients with coronary artery dise ase [J]. N Engl J Med, 2004, 350(3): 221-231.